Steve Egge, MBA

Mr. Egge joined INOVIO in 2024. Previously, he was at Sumitomo Pharma (formerly Myovant Sciences, acquired by Sumitovant Biopharma, a subsidiary of Sumitomo Pharma, in 2023), where as Senior Vice President and General Manager for Women’s Health he was responsible for building the commercial leadership team, accelerating the launch of Myfembree^® and helping lead the company’s expansion into new indications. Mr. Egge was at Merck for twenty years, where he held a number of senior commercial leadership roles, including leading Merck’s HPV Vaccines Franchise and serving as Chief Marketing Officer for the Vaccine Division, where he oversaw launches for new indications for GARDASIL^®, a re-launch of ZOSTAVAX^®, and launch planning for GARDASIL9^® and VAXELIS^®. Mr. Egge also served as Global Commercial Head for Merck’s Fertility Franchise, where he oversaw the launch of ELONVA^® in ex-U.S. markets. After Merck, Mr. Egge served as Senior Vice President at Genfit Corp., a French biotech company focused on liver diseases, where he led commercial planning and business development.

Mr. Egge earned an MBA in Marketing and Strategy from the Carlson School of Management at the University of Minnesota and a Bachelor of Science in Business Administration from North Dakota State University.